Clinical trials: Neuroinflammatory Response
- Condition Neuroinflammatory Response
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.
- Trial name
- NCT00616421
- Testing
- MenACWY-CRM, Licensed meningococcal ACWY vaccine
- Where
- 68 sites in United States, Canada
- Volunteers
- 2,907 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pneumonia, Bacterial
Study Evaluating Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Filipino Children
Evaluation of the carriage rate of Streptococcus pneumoniae in the nasopharynx of healthy children and the carriage rate and distribution of Streptococcus pneumoniae serotypes
- Trial name
- NCT00724828
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Encephalitis, Tick-Borne
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
The purpose of this study is to evaluate the safety, immunogenicity and tolerability of TBE vaccines administered to children.
- Trial name
- NCT00311441
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Infections, Meningococcal
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents [who previously participated in…
- Trial name
- NCT02446743
- Testing
- rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
- Where
- 12 sites in Australia, Canada and 1 more
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis
Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.
- Trial name
- NCT01559831
- Testing
- IXIARO
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Neuroinflammatory Response
Safety & PK of Single Doses of MT1980
MT1980 is being developed as a treatment for neuroinflammation (an inflammatory response in the brain and/or spinal cord). Much research has focused on the central role of neuroinflammation in the pathogenesis of many conditions…
- Trial name
- NCT05429840
- Testing
- MT1980
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Monument Therapeutics Limited
Healthy
Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
- Trial name
- NCT00581035
- Testing
- Prevenar and Meningitec, Prevenar, Meningitec
- Volunteers
- 712 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Virus Diseases
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
The purpose of this study is to evaluate the 1 year immunogenicity persistence of Rabipur in children 6-17 years of age, and compare the Zagreb regimen with the Essen regimen.
- Trial name
- NCT03192371
- Testing
- Rabipur
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcemia
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
This study was designed to generate data for the assessment of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) when given to adults aged 18 to 55 years.
- Trial name
- NCT00772629
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tick-borne Encephalitis (TBE)
TBE Seropersistence up to 10 Years After First Booster in Adults
The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.
- Trial name
- NCT01582698
- Testing
- FSME-IMMUN 0.5 ml
- Where
- 2 sites in Poland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningitis, Meningococcemia
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
This study was designed to evaluate the antibody response to a Menactra® booster dose in participants who previously received one dose of Menactra® or Menomune® as adolescents 3 years earlier in Study MTA02.
- Trial name
- NCT00777790
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 9 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Meningitis
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
The primary objective was to evaluate the persistence of bactericidal antibodies in children 40 and 60 months of age previously enrolled in the V59P14 (NCT00474526) study who received Novartis MenACWY Conjugate Vaccine.
- Trial name
- NCT01148017
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
- Where
- 19 sites in United States
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Japanese Encephalitis
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
This is a randomized, open-label Phase 3 study including children aged >9 months to <17 years and 7 months who have been vaccinated with IXIARO in study IC51-323.
- Trial name
- NCT01296360
- Testing
- IXIARO
- Where
- 3 sites in Philippines
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Meningococcal Meningitis, Meningococcal Infections
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
This study will evaluate the safety and immune response of Novartis Meningococcal ACWY conjugate vaccine in healthy adolescents and adults.
- Trial name
- NCT00474487
- Testing
- Meningococcal ACWY Polysaccharide Vaccine, MenACWY CRM (19 to 55 years), Meningococcal ACWY Conjugate Vaccine
- Where
- 2 sites in Argentina, Colombia
- Volunteers
- 2,831 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis
A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)
The main purpose of this study is to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years.
- Trial name
- NCT06995430
- Testing
- rMenB+OMV NZ vaccine
- Where
- 17 sites in Finland, Italy and 2 more
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
The purpose of this study is to assess: TBE antibody persistence 24, 34, 46 and 58 months (as applicable) after the first booster TBE vaccination with FSME-IMMUN 0.5ml given in Study 223, by means of ELISA (IMMUNOZYM FSME IgG)…
- Trial name
- NCT00503529
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 2 sites in Poland
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Meningococcal
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with…
- Trial name
- NCT03621670
- Testing
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 1,196 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline